Latest PSNC News

Visit PSNC website
  • Following the announcement that a further ten new Serious Shortage Protocols (SSPs) were issued on 20 May 2022, the NHS Business Services Authority (NHSBSA) have now published the endorsement guidance for the new SSPs on the NHSBSA’s website. Due to the number of different HRT SSPs available for affected HRT medicine, pharmacists must ensure that they...
  • The Department of Health and Social Care (DHSC) has today (24/05/2022) granted the following list of price concessions: Drug Pack size Price Concession Amoxicillin 250mg/5ml oral suspension sugar free 100 £1.68 Co-tenidone 100mg/25mg tablets 28 £1.42 Exemestane 25mg tablets 30 £19.91 Famotidine 20mg tablets 28 £16.25 Famotidine 40mg tablets 28 £28.54 Febuxostat 80mg tablets 28...
  • The World Pharmacy Council (WPC), working with Pfizer, is asking community pharmacists from around the world to contribute to the future direction of the sector. This survey is the first of its kind and aims to collect information on community pharmacists’ attitudes, experiences, and support requirements in relation to the provision of vaccination services. The responses...
  • In response to significant ongoing disruption to the supply of some Hormone Replacement Therapy (HRT) medicines, the Department of Health and Social Care (DHSC) has issued a further ten new Serious Shortage Protocols (SSPs). Following the three HRT SSPs issued at the end of April 2022, the ten new SSPs, introduced with immediate effect, allow...
  • PSNC Chief Executive Janet Morrison has recorded a video message for community pharmacy contractors about her personal reflections on the proposals for the future of PSNC and LPCs made by the Pharmacy Representation Review Steering Group (RSG). In the video, Janet recognises the proposals as sensible and practical steps that any modern and forward-thinking sector...
  • A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 15 Issue 10 May 2022) has been published and includes articles on: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia COVID-19 vaccines and medicines: updates for May 2022 Letters and medicine...